The combined company will operate as Coeptis Therapeutics Holdings, Inc. and began trading on the Nasdaq Global Market under the ticker symbol “COEP”
Wexford, Pennsylvania and Miami, October 31 March 2022 /PRNewswire/ – Coeptis Therapeutics, Inc. Biopharmaceutical company Coeptis (“Coeptis”) today announced the completion of its business combination with Bull Horn Holdings Corp. (NASDAQ: BHSE), a special purpose acquisition company (“Bull Horn”). For business combination purposes, the combined company has been renamed “Coeptis Therapeutics Holdings, Inc.”. (the “Company”) and its public shares and warrants are expected to begin trading today on the Nasdaq Global Market under the ticker symbols “COEP” and “COEPW,” October 31st2022. The company will continue to primarily focus on developing innovative cell therapy platforms for cancer patients.
For the purposes of the business combination, former Coeptis shareholders exchanged their common stock for Bull Horn’s common stock at a price of 2.96851721 for 1. With approximately 19.5 million shares of common stock issued and outstanding following the business combination, former Coeptis shareholders now own approximately 88% of the company, while existing Bull Horn shareholders own approximately 12%.
“This is an important step for Coeptis as we seek to be a leader in developing next-generation cancer cell therapy technologies. This transaction follows our recent licensing of SNAP-CAR, our multi-antigen CAR T technology platform, for the company we envision provide a springboard for active periods,” said David Mehalic, who will lead the company as CEO and Chairman. “Critically, the merger with Bull Horn enables our shares to be listed on the Nasdaq Global Market. Listing on the Nasdaq is our way of driving long-term shareholder value by potentially increasing our profile in the investment community. A key aspect of our goal to increase the liquidity of our stock and expand our shareholder base.”
After the business combination is completed, David Mehalic will serve as chief executive officer and chairman, and the remainder of the Coeptis executive team will continue with the company in the roles they held at Coeptis prior to the business combination. Christopher CallisBull Horn’s chief financial officer and director, will serve on the company’s board of directors.
In light of closing of business combination, Bull Horn cancels scheduled November 2, 2022to vote on amendments to its amended and restated Memorandum of Association and Articles of Association to extend the deadline for completion of Bull Horn’s initial business combination.
consultant
Ellenoff Grossman & Schole LLP served as legal counsel to Bull Horn, and Master Sirig & Fein LLP acted as legal counsel to Coeptis. JonesTrading Institutional Services LLC advised Bull Horn on capital markets and Bridgeway Capital Partners advised Coeptis on the business combination.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc. and its subsidiaries, including Coeptis Therapeutics, Inc. Coeptis Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative cancer cell therapy platforms that have the potential to disrupt traditional treatment paradigms and improve patient outcomes.The company’s product portfolio and rights focus on a generic multi-antigen CAR T technology that has gained University of Pittsburgh (SNAP-CAR), as well as cell therapy technologies (CD38-GEAR-NK) and in vitro diagnostics (CD38-Diagnostic) for CD38-related cancers, which the company is developing with VyGen-Bio and leading medical researchers Karolinska InstituteThe company’s business model is aimed at expanding its product rights and offerings, particularly those targeting cancer, through licensing agreements, licensing agreements and co-development relationships, and through strategic partnerships.The company was established in 2017 and is headquartered in Wexford, Pennsylvania. For more information about the company, please visit https://coeptistx.com/.
Caution Regarding Forward-Looking Statements
This press release and our management’s statements thereon contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements about our plans, objectives, objectives, strategies, future events or performance, as well as underlying assumptions and other statements other than statements of historical fact. When we use expressions such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions, these words are not just As with historical issues, we are making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties that could cause actual results to differ materially, and may even differ materially, from our expectations discussed in the forward-looking statements. Factors that could cause such differences include, but are not limited to: (1) the inability of the Company’s securities to obtain or maintain a listing on the Nasdaq Global Market after the business combination; (2) the business combination that disrupts Coeptis’ current plans and Operational risks; (3) Unable to confirm the expected benefits of the business combination, which may be affected by factors such as competition, the company’s economic growth and management growth, and the ability to hire and retain key employees; (4) Coeptis’s product under development failed (5) Expenses related to business combinations; (6) Changes in applicable laws and regulations; (7) The company may be subject to other economic, business and (8) The impact of the global COVID-19 pandemic on any of the above risks and other risks and uncertainties identified in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”). The factors listed above are not exclusive. All forward-looking statements are subject to material uncertainties and risks, including, but not limited to, risks contained or to be contained in the company’s reports and other filings with the Securities and Exchange Commission. For these reasons, among other things, investors should be careful not to place undue reliance on any forward-looking statements in this press release. Additional factors are discussed in the company’s filings with the Securities and Exchange Commission, or to be filed, which are available at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable law, regulation or rule.
contact details
Coeptis Therapeutics Holdings, Inc.
investor
Tiberend Strategy Consultants
Jon Nugent
[email protected]
media
David plans Leah
[email protected]
SourceCoeptis Therapeutics
